The FDA declared the application, as it stands, not approved and is providing guidance on information needed to resolve the issues.
Based in New Jersey, Daiichi Sankyo is a pharmaceutical manufacture working to address unmet health care needs.
FDA rejects Daiichi Sankyo's application for pain medication
The U.S. Food and Drug Administration
issued a complete response letter in response to Daiichi Sankyo's new drug
application regarding CL-108, a drug used in treating and managing pain.
The FDA declared the application, as it stands, not approved and is providing guidance on information needed to resolve the issues.
Based in New Jersey, Daiichi Sankyo is a pharmaceutical manufacture working to address unmet health care needs.
The FDA declared the application, as it stands, not approved and is providing guidance on information needed to resolve the issues.
Based in New Jersey, Daiichi Sankyo is a pharmaceutical manufacture working to address unmet health care needs.
Alerts Sign-up